574745-97-4

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Chloro-6-hydroxy-7-methoxyquinazoline is used as an intermediate in the synthesis of pharmaceuticals for its potential biological and pharmacological activities. Its unique chemical structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Synthesis:
This chemical compound is also utilized in the synthesis of agrochemicals, contributing to the development of new pesticides or other agricultural products that can improve crop yield and protect plants from diseases and pests.
Used in Disease Treatment Research:
4-Chloro-6-hydroxy-7-methoxyquinazoline is used as a therapeutic agent in research for the treatment of various diseases due to its demonstrated antiproliferative and anti-inflammatory properties. Its potential use in disease treatment is currently under investigation to explore its full range of applications and effectiveness.

Upstream product

• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 

Downstream Products

• 692059-41-9 6-(3-chloropropoxy)-4-chloro-7-methoxyquinazoline 
• 199327-59-8 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline 
• 894426-67-6 4-chloro-7-methoxy-6-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 
• 1355221-14-5 C₂₈H₃₂N₆O₅ 
• 1355221-13-4 C₂₄H₂₅N₅O₆ 
• 848491-25-8 N-(3-chloro-2,4-difluorophenyl)-7-methoxy-6-(piperidin-4-yloxy)quinazoline-4-amine 
• 609767-48-8 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-[(piperidin-4-yl)oxy]quinazoline 
• 909863-45-2 4-(5-chloro-2-fluoroanilino)-7-methoxy-6-[(piperidin-4-yl)oxy]quinazoline 
• 1441146-53-7 4-(3-chloroanilino)-7-methoxy-6-[(piperidin-4-yl)oxy]quinazoline 
• 612501-51-6 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-(piperidin-3-yloxy)quinazoline 
• 1441146-81-1 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-(pyrrolidin-3-yloxy)quinazoline 
• 1441146-87-7 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-[2-(N-methylamino)ethoxy]quinazoline 
• 609767-43-3 6-[(1-tert-butoxycarbonylpiperidin-4-yl)oxy]-4-(3-chloro-4-fluoroanilino)-7-methoxyquinazoline 
• 909863-42-9 C₂₅H₂₈ClFN₄O₄ 

Relevant academic research and scientific papers

Preparation method of lung cancer drug AZD3759

The present invention provides a method for preparing a lung cancer drug AZD3759. Using compounds of formula VIII and compounds of formula V. as raw materials, after hydrolysis reaction, condensation reaction, ammonization reaction, acidolysis reaction, methylation reaction, compound of formula I AZD3759 was obtained. The method has a novel route, simple response, environmental friendliness and high yield, which is suitable for industrial large-scale production.

QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

Preparation method of tyrosine kinase inhibitor AZD3759

The invention provides a preparation method of a tyrosine kinase inhibitor AZD3759, and relates to the field of medicinal chemistry. The preparation method comprises the following steps: by taking 3,4-dihydro-7-methoxy-4-oxoquinazoline-6-alcohol acetate as a raw material, carrying out a chlorination reaction and a hydrolysis reaction to obtain 4-chloro-7-methoxyquinazoline-6-alcohol (a compound 3); taking (R)-(-)-2-methylpiperazine as a raw material, and obtaining (R)-4-chlorocarbonyl-3-tert-butyl formate (compound 6) through a nucleophilic addition-elimination reaction and a chloroformylation reaction; carrying out an esterification reaction on the compound 3 and the compound 6 to obtain a compound 7; carrying out a Boc removal reaction and a methylation reaction on the compound 7 to obtain a compound 9; and carrying out alkylation reaction on the compound 9 and 2-fluoro-3-chloroaniline to obtain AZD3759. The method has the advantages of cheap and accessible raw materials and lower cost; sodium cyanoborohydride is not used in the reaction process, so that the method is more environment-friendly and is beneficial to industrial large-scale production.

Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor of Phosphodiesterase-10

Accurate prediction of absolute protein-ligand binding free energy could considerably enhance the success rate of structure-based drug design but is extremely challenging and time-consuming. Free energy perturbation (FEP) has been proven reliable but is limited to prediction of relative binding free energies of similar ligands (with only minor structural differences) in binding with a same drug target in practical drug design applications. Herein, a Gaussian algorithm-enhanced FEP (GA-FEP) protocol has been developed to enhance the FEP simulation performance, enabling to efficiently carry out the FEP simulations on vanishing the whole ligand and, thus, predict the absolute binding free energies (ABFEs). Using the GA-FEP protocol, the FEP simulations for the ABFE calculation (denoted as GA-FEP/ABFE) can achieve a satisfactory accuracy for both structurally similar and diverse ligands in a dataset of more than 100 receptor-ligand systems. Further, our GA-FEP/ABFE-guided lead optimization against phosphodiesterase-10 led to the discovery of a subnanomolar inhibitor (IC50 = 0.87 nM, ~2000-fold improvement in potency) with cocrystal confirmation.

Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1

The ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) was recently shown to promote mineralization of the aortic valve, hence, its inhibition represents a significant target. A quinazoline-4-piperidine sulfamide compound (QPS1) has been described as a specific and non-competitive inhibitor of NPP1. We report herein the synthesis and in vitro inhibition studies of novel quinazoline-4-piperidine sulfamide analogues using QPS1 as the lead compound. Of the 26 derivatives prepared, four compounds were found to have Ki 105 nM against human NPP1.

Kuikui zuo lin kind of target anti- tumor compound and its preparation method and application (by machine translation)

The present invention provides a chemical formula (I) indicated by the kuikui zuo lin kind of target anti- tumor compound and its preparation method, in particular to EGFR, HER - 2 and DNA multi-target anti- tumor compounds, also provides a method for preparing the same and in the application of the anti-tumor medicament. Studies show that the compounds of the invention have significant anti-tumor activity, metabolic stability relative to the reference substance EMB - 3 is improved notably. (by machine translation)

Novel quinazoline derivative LU1501, as well as preparation method and application thereof

The invention discloses a novel quinazoline derivative LU1501, as well as a preparation method and application thereof. The chemical name of the novel quinazoline derivative LU1501 is N-[(4-fluorophenyl)-methyl]-4-N-{7-methoxy-6-[(2-pyrrolidine-1-yl)-ethoxy]quinazoline-4-yl}benzene-1,4-diamine. The quinazoline derivative as well as pharmaceutically acceptable salts, solvates and hydrates thereof have excellent anti-tumor in-vitro and in-vivo activities on MCF-7, SK-BR-3, A549, HCT 116, U-118MG, U-87MG and MDA-MB-468, and have a relatively good application prospect in preparation of anti-tumor medicines.

A novel quinazoline derivative LU1509 and its preparation method and application (by machine translation)

The invention discloses a novel quinazoline derivative LU1509 and its preparation method, its chemical named N-4 - [(4-aminophenyl) methoxy] phenyl-7-methoxy-6 - [(2-pyrrolidin-1-yl) ethoxyl] quinazolin-4-amine. Quinazoline derivatives of the present invention and its pharmaceutically acceptable salts, solvates, and hydrate the MCF-7, SK-BR-3, A549, HCT? 116, MDA-MB-468 has outstanding kilograms of in vivo anti-tumor, anti-tumor drug in the preparation has better application prospect. (by machine translation)

Novel quinazoline derivative LU1507 as well as preparation method and application thereof

The invention discloses a novel quinazoline derivative LU1507 as well as a preparation method thereof. The quinazoline derivative LU1507 is chemically named 4-{4-[(7-methoxy)-6-[2-pyrrrolidine-1-yl)hydroxyethyl]quinazoline-4-yl}aminophenyl amino methylphenol. The quinazoline derivative as well as pharmaceutically acceptable salts, solvates and hydrates thereof has excellent in-vitro and in-vivo anti-tumor activity for MCF-7, SK-BR-3, A549, HCT 116, A172 and U-87 MG and has brighter application prospect in preparation of anti-tumor drugs.

A novel quinazoline derivative LU1505 and its preparation method and application (by machine translation)

The invention discloses a novel quinazoline derivative LU1505 and its preparation method, its chemical named N-{ [(4-dimethylamino) phenyl] methyl} - 4-N - [7-methoxy-6 - (2-pyrrolidin-1-yl) ethoxyl] quinazolin -4 yl} benzene -1,4-diamine. Quinazoline derivatives of the present invention and its pharmaceutically acceptable salts, solvates, and hydrate the MCF-7, SK-BR-3, A172, HCT? 116, U -118 mg, U -87 mg, MDA-MB-468 has outstanding kilograms of in vivo anti-tumor, anti-tumor drug in the preparation has better application prospect. (by machine translation)